Home › Funds › Vestal Point Capital, LP › ZBIO
Vestal Point Capital, LP position in ZBIO
ZENAS BIOPHARMA INC · Health Care
Vestal Point Capital, LP reported holding 395,000 shares of ZBIO (ZENAS BIOPHARMA INC) in its Q3 2026 13F filing — a position valued at US$10.7M, representing 0.28% of its reported portfolio and ranking #37 among its reported holdings. Vestal Point Capital, LP has disclosed ZBIO holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Vestal Point Capital, LP's ZBIO position evolved
Vestal Point Capital, LP first disclosed a stake in ZBIO in Q1 2026 at 200,000 shares (US$3.9M). The position peaked in Q3 2026 at 395,000 shares, worth US$10.7M. Across 3 filings, Vestal Point Capital, LP increased the stake 2 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 395,000 shares valued at US$10.7M — an increase of 30,000 shares quarter over quarter.. Notable position changes include a 82% increase in Q2 2026 (shares rose 6% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 200.00K | $3.91M | New |
| Q2 2026 | 365.00K | $9.26M | Add |
| Q3 2026 | 395.00K | $10.65M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ZBIO and 13F data
ZBIO (ZENAS BIOPHARMA INC) is a Health Care company. 59 other funds we track also report a position in ZBIO — the largest reported positions include SR ONE CAPITAL MANAGEMENT, LP (US$135.9M), NEA Management Company, LLC (US$108.5M), DEERFIELD MANAGEMENT COMPANY, L.P. (US$85.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ZBIO
- SR ONE CAPITAL MANAGEMENT, LP 5.04M sh · $135.87M · Q3 2026
- NEA Management Company, LLC 4.02M sh · $108.51M · Q3 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 67.20M sh · $85.74M · Q3 2026
- Enavate Sciences GP, LLC 2.92M sh · $78.73M · Q3 2026
- Royalty Pharma Sub-Manager, LLC 2.39M sh · $64.41M · Q3 2026
- Fairmount Funds Management LLC 2.37M sh · $63.96M · Q3 2026
- NVP Associates, LLC 1.84M sh · $49.58M · Q3 2026
- Context Capital Management, LLC 31.05M sh · $39.70M · Q3 2026
- Graham Capital Management, L.P. 21.25M sh · $27.32M · Q3 2026
- EcoR1 Capital, LLC 789.50K sh · $21.29M · Q3 2026
- ArrowMark Colorado Holdings LLC 527.98K sh · $14.24M · Q3 2026
- Rock Springs Capital Management LP 502.08K sh · $13.54M · Q3 2026
More on Vestal Point Capital, LP
FAQ
How long has Vestal Point Capital, LP held ZBIO?
Vestal Point Capital, LP has disclosed ZBIO holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
What is Vestal Point Capital, LP's current position in ZBIO?
As of Q3 2026, Vestal Point Capital, LP holds 395.00K shares of ZBIO (ZENAS BIOPHARMA INC), valued at $10.65M, representing 0.28% of its reported portfolio and ranking #37.
Has Vestal Point Capital, LP been buying or selling ZBIO?
In the latest 13F filing (Q3 2026), Vestal Point Capital, LP increased its position in ZBIO. The position peaked in Q3 2026 at 395.00K shares.
Which other funds hold ZBIO?
Other major institutional holders of ZBIO include SR ONE CAPITAL MANAGEMENT, LP, NEA Management Company, LLC, DEERFIELD MANAGEMENT COMPANY, L.P., among 59 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.